Platelet factor 4 localization in carotid atherosclerotic plaques: Correlation with clinical parameters

Thrombosis and Haemostasis

Volumn 90, Issue 6, 2003, Pages 1112-1120

  Pitsilos, Stephanie ^a   Hunt, Jennifer ^b   Mohler, Emile R ^a   Prabhakar, Anand M ^a   Poncz, Mortimer ^a   Dawicki, Jennine ^a   Khalapyan, Tigran Z ^a   Wolfe, Megan L ^a   Fairman, Ronald ^a   Mitchell, Marc ^a   Carpenter, Jeffrey ^a   Golden, Michael A ^a   Cines, Douglas B ^a   Sachais, Bruce S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Atherosclerosis; Macrophage phagocytosis; Platelet activation markers; Vasculopathies

Indexed keywords

ANTITHROMBOCYTIC AGENT; CHEMOKINE; FIBRINOGEN RECEPTOR; LOW DENSITY LIPOPROTEIN; NEUTROPHIL ACTIVATING PROTEIN 2; PROTEIN; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTOPSY; CALCIFICATION; CAROTID ARTERY DISEASE; CLINICAL EXAMINATION; CORRELATION FUNCTION; CYTOPLASM; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING; STENOSIS; VASCULAR ENDOTHELIUM;

EID: 0347043610     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-02-0069     Document Type: Article

References (27)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama 2001; 285 (19): 2486-97.
2. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-8.
3. Harker LA. Inhibitors of platelet function in the prevention of arterial thrombosis. Series Haematologica 1975; 8(3): 105-24.
4. Sinzinger H, Kaliman J, Fitscha P, O'Grady J. Diminished platelet residence time on active human atherosclerotic lesions in-vivo - Evidence for an optimal dose of aspirin? Prostaglandins Leukotrienes & Essential Fatty Acids 1988; 34 (2): 89-93.
5. Chesterman CN, Berndt MC. Platelet and vessel wall interaction and the genesis of atherosclerosis. Clin Haematol 1986; 15 (2): 323-53.
6. Sevitt S. Platelets and foam cells in the evolution of atherosclerosis. Histological and immunohistological studies of human lesions. Atherosclerosis 1986; 61 (2): 107-15.
7. Sachais BS. Platelet-endothelial interactions in atherosclerosis. Curr Atheroscler Rep 2001; 3(5): 412-6.
8. Holvoet P, Collen D. Thrombosis and atherosclerosis. Current Opinion in Lipidology 1997; 8(5): 320-8.
9. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362(6423): 801-9.
10. Fuhrman B, Brook GJ, Aviram M. Activated platelets secrete a protein-like factor that stimulates oxidized-LDL receptor activity in macrophages. Journal of Lipid Research 1991; 32(7): 1113-23.
11. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98(12): 1164-71.
12. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic Lesion formation. J Exp Med 2002; 196(7): 887-96
13. Sachais BS, Kuo A, Nassar T, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 3613-22.
14. Hunt JL, Fairman R, Mitchell ME, et al. Bone formation in carotid plaques: A clinicopathological study. Stroke 2002; 33(5): 1214-9.
15. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995; 15 (9): 1512-31.
16. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 2000; 95 (5): 1533-40.
17. Rao AK, Niewiarowski S, James P, et al. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 1983; 61: 1208-14.
18. Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thrombosis Research 1980; 19 (1-2): 129-37.
19. Rucinski B, Niewiarowski S, Strzyzewski M, Holt JC, Mayo KH. Human platelet factor 4 and its C-terminal peptides: Heparin binding and clrearance from the circulation Thrombosis & Haemostasis 1990; 63: 493-8.
20. Borgstrom P, Discipio R, Maione TE. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anti-Cancer Res 1998; 18(6A): 4035-41.
21. Hansell P, Maione TE, Borgstrom P. Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am J Physiol 1995; 269(3 Pt 2): H829-36.
22. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. Jama 1999; 282(21): 2035-42.
23. Wight TN. Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9(1): 1-20.
24. Deuel TF, Senior RM, Chang D, et al. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A 1981; 78(7): 4584-7.
25. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278 (8): 6187-93.
26. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308(6921): 81-106.
27. Anonymous. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321(3): 129-35.